These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18490647)

  • 61. Oleic acid suppresses overexpression of ERBB2 oncogene.
    Nelson R
    Lancet Oncol; 2005 Feb; 6(2):69. PubMed ID: 15704291
    [No Abstract]   [Full Text] [Related]  

  • 62. From the trastuzumab era to new target therapies: beyond revolution.
    Barni S; Petrelli F; Cabiddu M; Cazzaniga ME; Cremonesi M
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi1-4. PubMed ID: 17591799
    [No Abstract]   [Full Text] [Related]  

  • 63. New concepts in the treatment of breast cancer using high-dose chemotherapy.
    Peters WP; Dansey R
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S88-93. PubMed ID: 9272141
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance.
    Tan M; Yu D
    Adv Exp Med Biol; 2007; 608():119-29. PubMed ID: 17993237
    [No Abstract]   [Full Text] [Related]  

  • 65. Breast cancer: progress from NOAH study comes in twos.
    Hutchinson L
    Nat Rev Clin Oncol; 2014 Mar; 11(3):122. PubMed ID: 24492833
    [No Abstract]   [Full Text] [Related]  

  • 66. Walking the Tightrope Between Treatment Efficacy and Price.
    Bach PB
    J Clin Oncol; 2016 Mar; 34(9):889-90. PubMed ID: 26351328
    [No Abstract]   [Full Text] [Related]  

  • 67. First Therapy Targeting ERBB2-Low Breast Cancer Approved.
    Larkin HD
    JAMA; 2022 Sep; 328(9):819. PubMed ID: 36066537
    [No Abstract]   [Full Text] [Related]  

  • 68. Unfortunate Accident or Blessing in Disguise? Dramatic Response to Incidental Intrathoracic Delivery of Anti-HER2 Regimen.
    Tariq K; Keen R; Draper K; Tang SC
    J Glob Oncol; 2018 Sep; 4():1-4. PubMed ID: 30241190
    [No Abstract]   [Full Text] [Related]  

  • 69. Dose intensity ... and beyond.
    Hryniak W
    Cancer Invest; 2004; 22(4):648-9. PubMed ID: 15565823
    [No Abstract]   [Full Text] [Related]  

  • 70. Crossing the cancer cell membrane to improve clinical outcomes.
    Rowinsky EK
    Oncologist; 2003; 8 Suppl 3():1-4. PubMed ID: 14671223
    [No Abstract]   [Full Text] [Related]  

  • 71. Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?
    Arteaga CL
    J Clin Oncol; 2006 Aug; 24(23):3722-5. PubMed ID: 16847283
    [No Abstract]   [Full Text] [Related]  

  • 72. Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones.
    Hirte HW; Hotte SJ
    J Clin Oncol; 2008 Jul; 26(20):3301-2. PubMed ID: 18490647
    [No Abstract]   [Full Text] [Related]  

  • 73. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
    Storniolo AM; Pegram MD; Overmoyer B; Silverman P; Peacock NW; Jones SF; Loftiss J; Arya N; Koch KM; Paul E; Pandite L; Fleming RA; Lebowitz PF; Ho PT; Burris HA
    J Clin Oncol; 2008 Jul; 26(20):3317-23. PubMed ID: 18490651
    [TBL] [Abstract][Full Text] [Related]  

  • 74. How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer.
    Cortes J; Baselga J
    J Clin Oncol; 2009 Nov; 27(33):5492-4. PubMed ID: 19786653
    [No Abstract]   [Full Text] [Related]  

  • 75. A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).
    Moulder SL; Arteaga CL
    Clin Breast Cancer; 2003 Jun; 4(2):142-5. PubMed ID: 12864943
    [No Abstract]   [Full Text] [Related]  

  • 76. Advances in HER2-positive breast cancer.
    Sledge GW
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):98-100. PubMed ID: 18347559
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.